Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

Yuflyma is a high-concentration and citrate-free formulation of Humira biosimilar, approved for multiple inflammatory ...

This week has seen the launch of new and lower-priced biosimilars to AbbVie ... two pre-filled pens or syringes. This is, according to the two companies, an 85% discount on Humira’s list ...

my overall assessment is that the upside potential and downside risks for AbbVie Inc. are about balanced under current conditions. To recap, the key downside risks are the decline of the Humira ...

The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

Fears that Humira biosimilars will erode AbbVie's top line are overblown, an analyst said Monday as he reiterated his outperform rating on AbbVie stock. Please watch the video at Investors.com ...

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...

AbbVie has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are ...